Anabel is a Reporter, working across the six Citeline publications. She is a recent graduate from the University of Exeter and holds a BA English degree. Since graduating, Anabel has also completed an editorial internship with the In Vivo team. Before joining Norstella she spent the past year as Editor-in-Chief of her university’s student paper, Exeposé, managing an editorial team to produce a 32-page paper on a fortnightly basis.
Latest from Anabel Costa-Ferreira
As the race to transform Duchenne muscular dystrophy care accelerates, Santhera Pharmaceuticals’ chief medical officer Shabir Hasham discusses how treatment is evolving, why combination therapies may define the next era and what it will take to improve life for patients and families living with DMD.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip. After extensive coverage of the Annual JPM Healthcare Conference in San Francisco, we also highlight some of the insightful and memorable quotes across the week.
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.
Canada’s health care products regulator is seeking to strengthen its oversight of decentralized clinical trials.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.